Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
30/07/2026 07:48
BRIEF-Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO July 30 (Reuters) - Shield Therapeutics PLC STXS.L:
SHIELD THERAPEUTICS - Q2 AND H1 2026 TRADING UPDATE
SHIELD THERAPEUTICS PLC: ON TRACK FOR PROFITABILITY IN 2026
SHIELD THERAPEUTICS PLC: APPOINTMENT OF MICHAEL JENSEN AS CHIEF FINANCIAL OFFICER
SHIELD THERAPEUTICS PLC: H1 REVENUES OF $30.4M WITH 21% GROWTH IN PRESCRIPTIONS
Source text: ID:nRSd4576Oa
Further company coverage: STXS.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update